Casticin inhibits self-renewal of liver cancer stem cells from the MHCC97 cell line

He,Guicheng; Cao,Xiaocheng; He,Meng; Sheng,Xifeng; Wu,Youhua; Ai,Xiaohong

doi:10.3892/ol.2014.1972

Casticin inhibits self-renewal of liver cancer stem cells from the MHCC97 cell line

Authors:
- Guicheng He
- Xiaocheng Cao
- Meng He
- Xifeng Sheng
- Youhua Wu
- Xiaohong Ai
View Affiliations

Affiliations: Department of Oncology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China, Medical College, Hunan Normal University, Changsha, Hunan 410013, P.R. China, Department of Oncology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China
Published online on: March 14, 2014 https://doi.org/10.3892/ol.2014.1972
Pages: 2023-2028

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Casticin exerts anticarcinogenic activity in several types of cancers, including human hepatocellular carcinoma (HCC). The aim of the present study was to investigate the effects of casticin, which is derived from Fructus Viticis Simplicifoliae, on the self‑renewal capacity of liver cancer stem cells (LCSCs) derived from the HCC MHCC97 cell line. The present study demonstrated that casticin significantly inhibited the proliferation of LCSCs from the MHCC97 cell line in a dose‑dependent manner (P<0.05), the half maximal inhibitory concentration of the parental cells and LCSCs was 17.9 and 0.5 µmol̸l, respectively. Furthermore, casticin reduced the sphere‑forming capacity of LCSCs and downregulated β‑catenin protein expression in a concentration‑dependent manner. Lithium chloride, an agonist known to activate the Wnt̸β‑catenin signaling pathway, attenuated the casticin‑induced downregulation of β‑catenin protein expression and inhibited the self‑renewal capacity. To the best of our knowledge, the present study is the first to demonstrate that casticin effectively eradicates LCSCs and β‑catenin was identified as the potential target. Thus, casticin may offer a novel therapeutic approach for the treatment of HCC.

View Figures

View References

1	Ma S, Chan KW and Guan XY: In search of liver cancer stem cells. Stem Cell Rev. 4:179–192. 2008. View Article : Google Scholar : PubMed/NCBI
2	Tomuleasa C, Soritau O, Rus-Ciuca D, et al: Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis. 19:61–67. 2010.PubMed/NCBI
3	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
4	Lee TK, Castilho A, Ma S and Ng IO: Liver cancer stem cells: implications for a new therapeutic target. Liver Int. 29:955–965. 2009. View Article : Google Scholar : PubMed/NCBI
5	Mackillop WJ, Ciampi A, Till JE and Buick RN: A stem cell model of human tumor growth: implications for tumor cell clonogenic assays. J Natl Cancer Inst. 70:9–16. 1983.PubMed/NCBI
6	Gupta PB, Chaffer CL and Weinberg RA: Cancer stem cells: mirage or reality? Nat Med. 15:1010–1012. 2009. View Article : Google Scholar : PubMed/NCBI
7	Chiba T, Kita K, Zheng YW, et al: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 44:240–251. 2006. View Article : Google Scholar : PubMed/NCBI
8	Yang ZF, Ho DW, Ng MN, et al: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 13:153–166. 2008.
9	Ma S, Chan KW, Hu L, et al: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
10	Zhu Z, Hao X, Yan M, et al: Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 126:2067–2078. 2010.
11	Kimura O, Takahashi T, Ishii N, et al: Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci. 101:2145–2155. 2010.
12	Yang W, Yan HX, Chen L, et al: Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 68:4287–4295. 2008. View Article : Google Scholar : PubMed/NCBI
13	Haraguchi N, Ishii H, Mimori K, et al: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Investig. 120:3326–3339. 2010. View Article : Google Scholar : PubMed/NCBI
14	Salnikov AV, Kusumawidjaja G, Rausch V, et al: Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 275:185–193. 2009. View Article : Google Scholar
15	Pellegrino R, Brusasco V, Viegi G, et al: Definition of COPD: based on evidence or opinion? Eur Respir J. 31:681–682. 2008. View Article : Google Scholar : PubMed/NCBI
16	Pharmacopoeia Commission of People’s Republic of China. Pharmacopoeia of the Peoples Republic of China. 1. China Chemical Industry Press; Beijing: 2010, (In Chinese).
17	Ye Q, Zhang QY, Zheng CJ, Wang Y and Qin LP: Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro. Acta Pharmacol Sin. 31:1564–1568. 2010. View Article : Google Scholar : PubMed/NCBI
18	Shen JK, Du HP, Yang M, Wang YG and Jin J: Casticin induces leukemic cell death through apoptosis and mitotic catastrophe. Ann Hematol. 88:743–752. 2009. View Article : Google Scholar : PubMed/NCBI
19	Yang J, Yang Y, Tian L, Sheng XF, Liu F and Cao JG: Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. World J Gastroenterol. 17:4298–4307. 2011. View Article : Google Scholar : PubMed/NCBI
20	Feng X, Zhou Q, Liu C and Tao ML: Drug screening study using glioma stem-like cells. Mol Med Rep. 6:1117–1120. 2012.PubMed/NCBI
21	Wang F, He L, Dai W-Q, et al: Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PloS One. 7:e506382012. View Article : Google Scholar : PubMed/NCBI
22	Naujokat C and Steinhart R: Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012:9506582012. View Article : Google Scholar : PubMed/NCBI
23	Wang Z, Li Y, Ahmad A, et al: Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat. 13:109–118. 2010. View Article : Google Scholar : PubMed/NCBI
24	Liu J, Kopecková P, Bühler P, et al: Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. Mol Pharm. 6:959–970. 2009. View Article : Google Scholar : PubMed/NCBI
25	Shen JK, Du HP, Yang M, Wang YG and Jin J: Casticin induces leukemic cell death through apoptosis and mitotic catastrophe. Ann Hematol. 88:743–752. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kobayakawa J, Sato-Nishimori F, Moriyasu M and Matsukawa Y: G2-M arrest and antimitotic activity mediated by casticin, a flavonoid isolated from Viticis Fructus (Vitex rotundifolia Linne fil). Cancer Lett. 208:59–64. 2004. View Article : Google Scholar : PubMed/NCBI
27	Mizrak D, Brittan M and Alison M: CD133: molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ma S, Tang KH, Chan YP, et al: miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 7:694–707. 2010.PubMed/NCBI
29	Li L, Ying J, Li H, et al: The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. Oncogene. 31:3901–3912. 2012. View Article : Google Scholar : PubMed/NCBI